Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

NCT ID: NCT01870778

Last Updated: 2018-03-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

6600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-02

Study Completion Date

2017-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase IIIb outcome study in AHF patients was designed as a multicenter, randomized, double-blind, placebo-controlled, event-driven study in order to assess the efficacy, safety and tolerability of intravenous infusion of serelaxin or placebo. The AHF patients randomized to either serelaxin or placebo in the study were followed for a period of 180 days, and were required to receive standard-of-care background HF management during both the index hospitalization and post discharge according to regional or local guidelines/institutional standards.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Serelaxin (RLX030)

Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.

Group Type EXPERIMENTAL

RLX030

Intervention Type DRUG

1 mg/mL solution in 6 mL vials

Placebo

Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo solution to serelaxin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RLX030

1 mg/mL solution in 6 mL vials

Intervention Type DRUG

Placebo

Matching placebo solution to serelaxin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 years of age, with body weight ≤160 kg
* Hospitalized for AHF with anticipated requirement of IV therapy for at least 48 hours; AHF is defined as including all of the following measured at any time between presentation (including the emergency department) and the end of screening:

* Persistent dyspnea at rest or with minimal exertion
* Pulmonary congestion on chest radiograph
* B-type natriuretic peptide (BNP) ≥500 pg/mL or N-terminal (NT)-proBNP ≥2000 pg/mL; for patients ≥ 75 years of age or with current atrial fibrillation (at the time of randomization), BNP ≥ 750 pg/mL or NT-proBNP ≥ 3,000 pg/mL
* Systolic BP ≥125 mmHg at the start and at the end of screening
* Able to be randomized within 16 hours from presentation to the hospital, including the emergency department
* Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode.

Exclusion Criteria

* Dyspnea primarily due to non-cardiac causes
* Known history of respiratory disorders requiring the daily use of IV or oral steroids (does not include inhaled steroids); need for intubation or the current use of IV or oral steroids for chronic obstructive pulmonary disease (COPD)
* Temperature \>38.5°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment
* Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment.
* AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate \<45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of \>130 beats per minute
* Patients with severe renal impairment defined as pre-randomization estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2 calculated using the Simplified Modification of Diet in Renal Disease (sMDRD) equation, and/or those receiving current or planned dialysis or ultrafiltration
* Patients with hematocrit \<25%, or a history of blood transfusion within the 14 days prior to screening, or active life-threatening GI bleeding.
* Known hepatic impairment (as evidenced by total bilirubin \> 3 mg/dL, or increased ammonia levels, if performed) or history of cirrhosis with evidence of portal hypertension such as varices.
* Significant, uncorrected, left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area \<1.0 cm2 or mean gradient \>40 mmHg on prior or current echocardiogram), and severe mitral stenosis
* Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated.
* Documented, prior to or at the time of randomization, restrictive amyloid myocardiopathy, OR acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (does NOT include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Huntsville, Alabama, United States

Site Status

Novartis Investigative Site

Montgomery, Alabama, United States

Site Status

Novartis Investigative Site

Tucson, Arizona, United States

Site Status

Novartis Investigative Site

Anaheim, California, United States

Site Status

Novartis Investigative Site

Fresno, California, United States

Site Status

Novartis Investigative Site

Loma Linda, California, United States

Site Status

Novartis Investigative Site

Los Angeles, California, United States

Site Status

Novartis Investigative Site

Los Angeles, California, United States

Site Status

Novartis Investigative Site

Los Angeles, California, United States

Site Status

Novartis Investigative Site

Northridge, California, United States

Site Status

Novartis Investigative Site

Palo Alto, California, United States

Site Status

Novartis Investigative Site

Sacramento, California, United States

Site Status

Novartis Investigative Site

San Diego, California, United States

Site Status

Novartis Investigative Site

San Diego, California, United States

Site Status

Novartis Investigative Site

San Diego, California, United States

Site Status

Novartis Investigative Site

Sylmar, California, United States

Site Status

Novartis Investigative Site

Walnut Creek, California, United States

Site Status

Novartis Investigative Site

Colorado Springs, Colorado, United States

Site Status

Novartis Investigative Site

Denver, Colorado, United States

Site Status

Novartis Investigative Site

Hartford, Connecticut, United States

Site Status

Novartis Investigative Site

Hartford, Connecticut, United States

Site Status

Novartis Investigative Site

Atlantis, Florida, United States

Site Status

Novartis Investigative Site

Jacksonville, Florida, United States

Site Status

Novartis Investigative Site

Jacksonville, Florida, United States

Site Status

Novartis Investigative Site

Jacksonville, Florida, United States

Site Status

Novartis Investigative Site

Sanford, Florida, United States

Site Status

Novartis Investigative Site

Sarasota, Florida, United States

Site Status

Novartis Investigative Site

Tampa, Florida, United States

Site Status

Novartis Investigative Site

Tampa, Florida, United States

Site Status

Novartis Investigative Site

Winter Haven, Florida, United States

Site Status

Novartis Investigative Site

Atlanta, Georgia, United States

Site Status

Novartis Investigative Site

Atlanta, Georgia, United States

Site Status

Novartis Investigative Site

Marietta, Georgia, United States

Site Status

Novartis Investigative Site

Chicago, Illinois, United States

Site Status

Novartis Investigative Site

Elk Grove Village, Illinois, United States

Site Status

Novartis Investigative Site

Oakbrook Terrace, Illinois, United States

Site Status

Novartis Investigative Site

Peoria, Illinois, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Muncie, Indiana, United States

Site Status

Novartis Investigative Site

Kansas City, Kansas, United States

Site Status

Novartis Investigative Site

Alexandria, Louisiana, United States

Site Status

Novartis Investigative Site

Baton Rouge, Louisiana, United States

Site Status

Novartis Investigative Site

Covington, Louisiana, United States

Site Status

Novartis Investigative Site

New Orleans, Louisiana, United States

Site Status

Novartis Investigative Site

Annapolis, Maryland, United States

Site Status

Novartis Investigative Site

Baltimore, Maryland, United States

Site Status

Novartis Investigative Site

Baltimore, Maryland, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

Novartis Investigative Site

Worcester, Massachusetts, United States

Site Status

Novartis Investigative Site

Detroit, Michigan, United States

Site Status

Novartis Investigative Site

Detroit, Michigan, United States

Site Status

Novartis Investigative Site

Detroit, Michigan, United States

Site Status

Novartis Investigative Site

Minneapolis, Minnesota, United States

Site Status

Novartis Investigative Site

Jackson, Mississippi, United States

Site Status

Novartis Investigative Site

Picayune, Mississippi, United States

Site Status

Novartis Investigative Site

Kansas City, Missouri, United States

Site Status

Novartis Investigative Site

St Louis, Missouri, United States

Site Status

Novartis Investigative Site

St Louis, Missouri, United States

Site Status

Novartis Investigative Site

St Louis, Missouri, United States

Site Status

Novartis Investigative Site

Omaha, Nebraska, United States

Site Status

Novartis Investigative Site

Brooklyn, New York, United States

Site Status

Novartis Investigative Site

Brooklyn, New York, United States

Site Status

Novartis Investigative Site

Kingston, New York, United States

Site Status

Novartis Investigative Site

New Hyde Park, New York, United States

Site Status

Novartis Investigative Site

Rochester, New York, United States

Site Status

Novartis Investigative Site

Stony Brook, New York, United States

Site Status

Novartis Investigative Site

The Bronx, New York, United States

Site Status

Novartis Investigative Site

The Bronx, New York, United States

Site Status

Novartis Investigative Site

Chapel Hill, North Carolina, United States

Site Status

Novartis Investigative Site

Durham, North Carolina, United States

Site Status

Novartis Investigative Site

Raleigh, North Carolina, United States

Site Status

Novartis Investigative Site

Canton, Ohio, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Cleveland, Ohio, United States

Site Status

Novartis Investigative Site

Columbus, Ohio, United States

Site Status

Novartis Investigative Site

Toledo, Ohio, United States

Site Status

Novartis Investigative Site

Portland, Oregon, United States

Site Status

Novartis Investigative Site

Abington, Pennsylvania, United States

Site Status

Novartis Investigative Site

Natrona Heights, Pennsylvania, United States

Site Status

Novartis Investigative Site

Philadelphia, Pennsylvania, United States

Site Status

Novartis Investigative Site

Philadelphia, Pennsylvania, United States

Site Status

Novartis Investigative Site

Wynnewood, Pennsylvania, United States

Site Status

Novartis Investigative Site

Providence, Rhode Island, United States

Site Status

Novartis Investigative Site

Warwick, Rhode Island, United States

Site Status

Novartis Investigative Site

Greenville, South Carolina, United States

Site Status

Novartis Investigative Site

Greenville, South Carolina, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Galveston, Texas, United States

Site Status

Novartis Investigative Site

Houston, Texas, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

Charlottesville, Virginia, United States

Site Status

Novartis Investigative Site

Falls Church, Virginia, United States

Site Status

Novartis Investigative Site

Lynchburg, Virginia, United States

Site Status

Novartis Investigative Site

Roanoke, Virginia, United States

Site Status

Novartis Investigative Site

Seattle, Washington, United States

Site Status

Novartis Investigative Site

Seattle, Washington, United States

Site Status

Novartis Investigative Site

Morgantown, West Virginia, United States

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Caba, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Carapachay, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Coronel Suárez, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

La Plata, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

San Martín, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

San Salvador de Jujuy, Jujuy Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Corrientes, , Argentina

Site Status

Novartis Investigative Site

Corrientes, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Formosa, , Argentina

Site Status

Novartis Investigative Site

Salta, , Argentina

Site Status

Novartis Investigative Site

San Miguel de Tucumán, , Argentina

Site Status

Novartis Investigative Site

Santa Fe, , Argentina

Site Status

Novartis Investigative Site

Santa Fe, , Argentina

Site Status

Novartis Investigative Site

Camperdown, New South Wales, Australia

Site Status

Novartis Investigative Site

Concord, New South Wales, Australia

Site Status

Novartis Investigative Site

Randwick, New South Wales, Australia

Site Status

Novartis Investigative Site

St Leonards, New South Wales, Australia

Site Status

Novartis Investigative Site

Herston, Queensland, Australia

Site Status

Novartis Investigative Site

Bedford Park, South Australia, Australia

Site Status

Novartis Investigative Site

Geelong, Victoria, Australia

Site Status

Novartis Investigative Site

Melbourne, Victoria, Australia

Site Status

Novartis Investigative Site

Murdoch, Western Australia, Australia

Site Status

Novartis Investigative Site

Perth, Western Australia, Australia

Site Status

Novartis Investigative Site

Innsbruck, Tyrol, Austria

Site Status

Novartis Investigative Site

Braunau am Inn, , Austria

Site Status

Novartis Investigative Site

Graz, , Austria

Site Status

Novartis Investigative Site

Linz, , Austria

Site Status

Novartis Investigative Site

Linz, , Austria

Site Status

Novartis Investigative Site

Salzburg, , Austria

Site Status

Novartis Investigative Site

Vienna, , Austria

Site Status

Novartis Investigative Site

Villach, , Austria

Site Status

Novartis Investigative Site

Wels, , Austria

Site Status

Novartis Investigative Site

Aalst, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Genk, , Belgium

Site Status

Novartis Investigative Site

Ghent, , Belgium

Site Status

Novartis Investigative Site

Kortrijk, , Belgium

Site Status

Novartis Investigative Site

Leuven, , Belgium

Site Status

Novartis Investigative Site

Mons, , Belgium

Site Status

Novartis Investigative Site

Goiânia, Goiás, Brazil

Site Status

Novartis Investigative Site

Curitiba, Paraná, Brazil

Site Status

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Novartis Investigative Site

Ribeirão Preto, São Paulo, Brazil

Site Status

Novartis Investigative Site

São José do Rio Preto, São Paulo, Brazil

Site Status

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Site Status

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Site Status

Novartis Investigative Site

Smolyan, Bulgaria, Bulgaria

Site Status

Novartis Investigative Site

Pazardzhik, , Bulgaria

Site Status

Novartis Investigative Site

Pleven, , Bulgaria

Site Status

Novartis Investigative Site

Plovdiv, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Varna, , Bulgaria

Site Status

Novartis Investigative Site

Calgary, Alberta, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Sainte-Foy, Quebec, Canada

Site Status

Novartis Investigative Site

Thetford-Mines, Quebec, Canada

Site Status

Novartis Investigative Site

Las Condes, Santiago Metropolitan, Chile

Site Status

Novartis Investigative Site

Santiago, , Chile

Site Status

Novartis Investigative Site

Medellín, Antioquia, Colombia

Site Status

Novartis Investigative Site

Barranquilla, , Colombia

Site Status

Novartis Investigative Site

Florida Blanca, , Colombia

Site Status

Novartis Investigative Site

Brno - Bohunice, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Frýdek-Místek, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Kladno, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Liberec, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Pardubice, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Prague, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Slaný, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Ústí nad Labem, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Ústí nad Orlicí, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Zlín, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Hradec Králové, CZE, Czechia

Site Status

Novartis Investigative Site

Benešov, , Czechia

Site Status

Novartis Investigative Site

Brno, , Czechia

Site Status

Novartis Investigative Site

Jihlava, , Czechia

Site Status

Novartis Investigative Site

Kolín, , Czechia

Site Status

Novartis Investigative Site

Pilsen, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Copenhagen NV, , Denmark

Site Status

Novartis Investigative Site

Glostrup Municipality, , Denmark

Site Status

Novartis Investigative Site

Glostrup Municipality, , Denmark

Site Status

Novartis Investigative Site

Randers, , Denmark

Site Status

Novartis Investigative Site

Amiens, , France

Site Status

Novartis Investigative Site

Besançon, , France

Site Status

Novartis Investigative Site

Béziers, , France

Site Status

Novartis Investigative Site

Bobigny, , France

Site Status

Novartis Investigative Site

Caen, , France

Site Status

Novartis Investigative Site

Chambray-lès-Tours, , France

Site Status

Novartis Investigative Site

La Tronche, , France

Site Status

Novartis Investigative Site

Le Chesnay, , France

Site Status

Novartis Investigative Site

Le Chesnay, , France

Site Status

Novartis Investigative Site

Lille, , France

Site Status

Novartis Investigative Site

Lille, , France

Site Status

Novartis Investigative Site

Nancy, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Pessac, , France

Site Status

Novartis Investigative Site

Pontoise, , France

Site Status

Novartis Investigative Site

Rouen, , France

Site Status

Novartis Investigative Site

Saint Herblain - Nantes, , France

Site Status

Novartis Investigative Site

Toulouse, , France

Site Status

Novartis Investigative Site

Tourcoing, , France

Site Status

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bad Krozingen, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Bitburg, , Germany

Site Status

Novartis Investigative Site

Bochum, , Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Brandenburg, , Germany

Site Status

Novartis Investigative Site

Bremen, , Germany

Site Status

Novartis Investigative Site

Coburg, , Germany

Site Status

Novartis Investigative Site

Detmold, , Germany

Site Status

Novartis Investigative Site

Dortmund, , Germany

Site Status

Novartis Investigative Site

Dortmund, , Germany

Site Status

Novartis Investigative Site

Dresden, , Germany

Site Status

Novartis Investigative Site

Erfurt, , Germany

Site Status

Novartis Investigative Site

Erfurt, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Frankfurt, , Germany

Site Status

Novartis Investigative Site

Frankfurt, , Germany

Site Status

Novartis Investigative Site

Frankfurt, , Germany

Site Status

Novartis Investigative Site

Freiburg im Breisgau, , Germany

Site Status

Novartis Investigative Site

Friedberg, , Germany

Site Status

Novartis Investigative Site

Füssen, , Germany

Site Status

Novartis Investigative Site

Göttingen, , Germany

Site Status

Novartis Investigative Site

Göttingen, , Germany

Site Status

Novartis Investigative Site

Greifswald, , Germany

Site Status

Novartis Investigative Site

Halle, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Heilbronn, , Germany

Site Status

Novartis Investigative Site

Jena, , Germany

Site Status

Novartis Investigative Site

Kiel, , Germany

Site Status

Novartis Investigative Site

Kleve, , Germany

Site Status

Novartis Investigative Site

Koeln-Nippes, , Germany

Site Status

Novartis Investigative Site

Langen, , Germany

Site Status

Novartis Investigative Site

Leipzig, , Germany

Site Status

Novartis Investigative Site

Leverkusen, , Germany

Site Status

Novartis Investigative Site

Limburg, , Germany

Site Status

Novartis Investigative Site

Ludwigshafen, , Germany

Site Status

Novartis Investigative Site

Lübeck, , Germany

Site Status

Novartis Investigative Site

Magdeburg, , Germany

Site Status

Novartis Investigative Site

Magdeburg, , Germany

Site Status

Novartis Investigative Site

Mainz, , Germany

Site Status

Novartis Investigative Site

Merseburg, , Germany

Site Status

Novartis Investigative Site

Mönchengladbach, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

Neuwied, , Germany

Site Status

Novartis Investigative Site

Oldenburg, , Germany

Site Status

Novartis Investigative Site

Regensburg, , Germany

Site Status

Novartis Investigative Site

Rüsselsheim am Main, , Germany

Site Status

Novartis Investigative Site

Tübingen, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Villingen-Schwenningen, , Germany

Site Status

Novartis Investigative Site

Weiden, , Germany

Site Status

Novartis Investigative Site

Witten, , Germany

Site Status

Novartis Investigative Site

Wuppertal, , Germany

Site Status

Novartis Investigative Site

Würzburg, , Germany

Site Status

Novartis Investigative Site

Zwickau, , Germany

Site Status

Novartis Investigative Site

Athens, GR, Greece

Site Status

Novartis Investigative Site

Larissa, GR, Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Chaïdári, , Greece

Site Status

Novartis Investigative Site

Thessaloniki, , Greece

Site Status

Novartis Investigative Site

Balatonfüred, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Cegléd, , Hungary

Site Status

Novartis Investigative Site

Debrecen, , Hungary

Site Status

Novartis Investigative Site

Kaposvár, , Hungary

Site Status

Novartis Investigative Site

Mátészalka, , Hungary

Site Status

Novartis Investigative Site

Pécs, , Hungary

Site Status

Novartis Investigative Site

Székesfehérvár, , Hungary

Site Status

Novartis Investigative Site

Szombathely, , Hungary

Site Status

Novartis Investigative Site

Zalaegerszeg, , Hungary

Site Status

Novartis Investigative Site

Dublin, , Ireland

Site Status

Novartis Investigative Site

Dublin, , Ireland

Site Status

Novartis Investigative Site

Galway, , Ireland

Site Status

Novartis Investigative Site

Lower Galilee, Israel, Israel

Site Status

Novartis Investigative Site

Ashkelon, , Israel

Site Status

Novartis Investigative Site

Hadera, , Israel

Site Status

Novartis Investigative Site

Haifa, , Israel

Site Status

Novartis Investigative Site

Jerusalem, , Israel

Site Status

Novartis Investigative Site

Jerusalem, , Israel

Site Status

Novartis Investigative Site

Nahariya, , Israel

Site Status

Novartis Investigative Site

Petah Tikva, , Israel

Site Status

Novartis Investigative Site

Rehovot, , Israel

Site Status

Novartis Investigative Site

Sefad, , Israel

Site Status

Novartis Investigative Site

Tel Aviv, , Israel

Site Status

Novartis Investigative Site

Tel Giborim, Holon, , Israel

Site Status

Novartis Investigative Site

Cortona, AR, Italy

Site Status

Novartis Investigative Site

Bergamo, BG, Italy

Site Status

Novartis Investigative Site

Brescia, BS, Italy

Site Status

Novartis Investigative Site

Gavardo, BS, Italy

Site Status

Novartis Investigative Site

Bolzano, BZ, Italy

Site Status

Novartis Investigative Site

Cremona, CR, Italy

Site Status

Novartis Investigative Site

Cona, FE, Italy

Site Status

Novartis Investigative Site

Foggia, FG, Italy

Site Status

Novartis Investigative Site

Florence, FI, Italy

Site Status

Novartis Investigative Site

Pozzilli, IS, Italy

Site Status

Novartis Investigative Site

Monza, MB, Italy

Site Status

Novartis Investigative Site

Milan, MI, Italy

Site Status

Novartis Investigative Site

Milan, MI, Italy

Site Status

Novartis Investigative Site

Vimercate, MI, Italy

Site Status

Novartis Investigative Site

Modena, MO, Italy

Site Status

Novartis Investigative Site

Perugia, PG, Italy

Site Status

Novartis Investigative Site

Pisa, PI, Italy

Site Status

Novartis Investigative Site

Parma, PR, Italy

Site Status

Novartis Investigative Site

Pavia, PV, Italy

Site Status

Novartis Investigative Site

Albano Laziale, RM, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Rimini, RN, Italy

Site Status

Novartis Investigative Site

Torino, TO, Italy

Site Status

Novartis Investigative Site

Trieste, TS, Italy

Site Status

Novartis Investigative Site

Udine, UD, Italy

Site Status

Novartis Investigative Site

Novara, , Italy

Site Status

Novartis Investigative Site

Guadalajara, Jalisco, Mexico

Site Status

Novartis Investigative Site

Mexico City, Mexico City, Mexico

Site Status

Novartis Investigative Site

San Luis Potosí City, San Luis Potosí, Mexico

Site Status

Novartis Investigative Site

Culiacán, Sinaloa, Mexico

Site Status

Novartis Investigative Site

San Luis Potosí City, , Mexico

Site Status

Novartis Investigative Site

Sneek, The Netherlands, Netherlands

Site Status

Novartis Investigative Site

Almelo, , Netherlands

Site Status

Novartis Investigative Site

Amersfoort, , Netherlands

Site Status

Novartis Investigative Site

Amsterdam, , Netherlands

Site Status

Novartis Investigative Site

Arnhem, , Netherlands

Site Status

Novartis Investigative Site

Deventer, , Netherlands

Site Status

Novartis Investigative Site

Gorinchem, , Netherlands

Site Status

Novartis Investigative Site

Groningen, , Netherlands

Site Status

Novartis Investigative Site

Haarlem, , Netherlands

Site Status

Novartis Investigative Site

Hardenberg, , Netherlands

Site Status

Novartis Investigative Site

Maastricht, , Netherlands

Site Status

Novartis Investigative Site

Nijmegen, , Netherlands

Site Status

Novartis Investigative Site

Rotterdam, , Netherlands

Site Status

Novartis Investigative Site

Venlo, , Netherlands

Site Status

Novartis Investigative Site

Zutphen, , Netherlands

Site Status

Novartis Investigative Site

Stavanger, , Norway

Site Status

Novartis Investigative Site

Lima Cercado, Lima region, Peru

Site Status

Novartis Investigative Site

Krakow, POL, Poland

Site Status

Novartis Investigative Site

Bialystok, , Poland

Site Status

Novartis Investigative Site

Grodzisk Mazowiecki, , Poland

Site Status

Novartis Investigative Site

Krakow, , Poland

Site Status

Novartis Investigative Site

Krakow, , Poland

Site Status

Novartis Investigative Site

Krakow, , Poland

Site Status

Novartis Investigative Site

Kłodzko, , Poland

Site Status

Novartis Investigative Site

Lodz, , Poland

Site Status

Novartis Investigative Site

Lódz, , Poland

Site Status

Novartis Investigative Site

Oława, , Poland

Site Status

Novartis Investigative Site

Puławy, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Wroclaw, , Poland

Site Status

Novartis Investigative Site

Włocławek, , Poland

Site Status

Novartis Investigative Site

Carnaxide - Linda-A-Velha, Lisbon District, Portugal

Site Status

Novartis Investigative Site

Vila Real, Portuigal, Portugal

Site Status

Novartis Investigative Site

Amadora, , Portugal

Site Status

Novartis Investigative Site

Coimbra, , Portugal

Site Status

Novartis Investigative Site

Covilha, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Penafiel, , Portugal

Site Status

Novartis Investigative Site

Porto, , Portugal

Site Status

Novartis Investigative Site

Viana do Castelo, , Portugal

Site Status

Novartis Investigative Site

Vila Nova de Gaia, , Portugal

Site Status

Novartis Investigative Site

Mayagüez, , Puerto Rico

Site Status

Novartis Investigative Site

Târgu Mureş, Mureș County, Romania

Site Status

Novartis Investigative Site

Tg. Mures, Mureș County, Romania

Site Status

Novartis Investigative Site

Arad, , Romania

Site Status

Novartis Investigative Site

Baia Mare, , Romania

Site Status

Novartis Investigative Site

Brasov, , Romania

Site Status

Novartis Investigative Site

Brăila, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Craiova, , Romania

Site Status

Novartis Investigative Site

Oradea, , Romania

Site Status

Novartis Investigative Site

Piteşti, , Romania

Site Status

Novartis Investigative Site

Timișoara, , Romania

Site Status

Novartis Investigative Site

Timișoara, , Romania

Site Status

Novartis Investigative Site

Timișoara, , Romania

Site Status

Novartis Investigative Site

Timișoara, , Romania

Site Status

Novartis Investigative Site

Barnaul, , Russia

Site Status

Novartis Investigative Site

Ivanovo, , Russia

Site Status

Novartis Investigative Site

Kemerovo, , Russia

Site Status

Novartis Investigative Site

Kemerovo, , Russia

Site Status

Novartis Investigative Site

Kirov, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Novosibirsk, , Russia

Site Status

Novartis Investigative Site

S.-Petersburg, , Russia

Site Status

Novartis Investigative Site

S.-Petersburg, , Russia

Site Status

Novartis Investigative Site

S.-Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Samara, , Russia

Site Status

Novartis Investigative Site

Saratov, , Russia

Site Status

Novartis Investigative Site

Tomsk, , Russia

Site Status

Novartis Investigative Site

Vladimir, , Russia

Site Status

Novartis Investigative Site

Voronezh, , Russia

Site Status

Novartis Investigative Site

Yaroslavl, , Russia

Site Status

Novartis Investigative Site

Yekaterinburg, , Russia

Site Status

Novartis Investigative Site

Košice, Slovak Republic, Slovakia

Site Status

Novartis Investigative Site

Liptovský Mikuláš, Slovak Republic, Slovakia

Site Status

Novartis Investigative Site

Topoľčany, Slovak Republic, Slovakia

Site Status

Novartis Investigative Site

Banská Bystrica, , Slovakia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Lučenec, , Slovakia

Site Status

Novartis Investigative Site

Martin, , Slovakia

Site Status

Novartis Investigative Site

Nitra, , Slovakia

Site Status

Novartis Investigative Site

Nové Zámky, , Slovakia

Site Status

Novartis Investigative Site

Prešov, , Slovakia

Site Status

Novartis Investigative Site

Rimavská Sobota, , Slovakia

Site Status

Novartis Investigative Site

Trnava, , Slovakia

Site Status

Novartis Investigative Site

Bloemfontein, Free State, South Africa

Site Status

Novartis Investigative Site

Durban, , South Africa

Site Status

Novartis Investigative Site

Johannesburg, , South Africa

Site Status

Novartis Investigative Site

Johannesburg, , South Africa

Site Status

Novartis Investigative Site

Umhlanga, , South Africa

Site Status

Novartis Investigative Site

Western Cape, , South Africa

Site Status

Novartis Investigative Site

Córdoba, Andalusia, Spain

Site Status

Novartis Investigative Site

Marbella, Andalusia, Spain

Site Status

Novartis Investigative Site

Málaga, Andalusia, Spain

Site Status

Novartis Investigative Site

Sanlúcar de Barrameda, Andalusia, Spain

Site Status

Novartis Investigative Site

Seville, Andalusia, Spain

Site Status

Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Novartis Investigative Site

Sant Joan Despí, Barcelona, Spain

Site Status

Novartis Investigative Site

Villamartín, Cadiz, Spain

Site Status

Novartis Investigative Site

León, Castille and León, Spain

Site Status

Novartis Investigative Site

Badalona, Catalonia, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

A Coruña, Galicia, Spain

Site Status

Novartis Investigative Site

Getafe, Madrid, Spain

Site Status

Novartis Investigative Site

Majadahonda, Madrid, Spain

Site Status

Novartis Investigative Site

El Palmar, Murcia, Spain

Site Status

Novartis Investigative Site

Alicante, Valencia, Spain

Site Status

Novartis Investigative Site

Valencia, Valencia, Spain

Site Status

Novartis Investigative Site

Valencia, Valencia, Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Jönköping, , Sweden

Site Status

Novartis Investigative Site

Linköping, , Sweden

Site Status

Novartis Investigative Site

Mölndal, , Sweden

Site Status

Novartis Investigative Site

Stockholm, , Sweden

Site Status

Novartis Investigative Site

Uppsala, , Sweden

Site Status

Novartis Investigative Site

Basel, , Switzerland

Site Status

Novartis Investigative Site

Bern, , Switzerland

Site Status

Novartis Investigative Site

Lausanne, , Switzerland

Site Status

Novartis Investigative Site

Sankt Gallen, , Switzerland

Site Status

Novartis Investigative Site

Pendik / Istanbul, Turkey, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Haydarpasa/Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Kocaeli, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Mersin, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Sivas, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

High Wycombe, Buckinghamshire, United Kingdom

Site Status

Novartis Investigative Site

Torquay, Devon, United Kingdom

Site Status

Novartis Investigative Site

Basingstoke, Hampshire, United Kingdom

Site Status

Novartis Investigative Site

Nottingham, Hampshire, United Kingdom

Site Status

Novartis Investigative Site

Blackburn, Lancashire, United Kingdom

Site Status

Novartis Investigative Site

Hardwick, Stockton On Tees, United Kingdom

Site Status

Novartis Investigative Site

Dudley, West Midlands, United Kingdom

Site Status

Novartis Investigative Site

Blackpool, , United Kingdom

Site Status

Novartis Investigative Site

Edinburgh, , United Kingdom

Site Status

Novartis Investigative Site

Glasgow, , United Kingdom

Site Status

Novartis Investigative Site

Kettering, , United Kingdom

Site Status

Novartis Investigative Site

Leicester, , United Kingdom

Site Status

Novartis Investigative Site

Liverpool, , United Kingdom

Site Status

Novartis Investigative Site

Liverpool, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

Manchester, , United Kingdom

Site Status

Novartis Investigative Site

Portsmouth, , United Kingdom

Site Status

Novartis Investigative Site

Swindon, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Bulgaria Canada Chile Colombia Czechia Denmark France Germany Greece Hungary Ireland Israel Italy Mexico Netherlands Norway Peru Poland Portugal Puerto Rico Romania Russia Slovakia South Africa Spain Sweden Switzerland Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Ravera A, Qin H, Ter Maaten JM, Santema BT, Adamo M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos GS, Pang PS, Greenberg BH, Gimpelewicz C, Severin T, Teerkink JR, Voors AA, Metra M. Clinical Presentation, Biomarker Trajectories, and Outcomes in Women and Men Hospitalized for Acute Heart Failure. JACC Heart Fail. 2025 Aug 21;13(10):102524. doi: 10.1016/j.jchf.2025.102524. Online ahead of print.

Reference Type DERIVED
PMID: 40845614 (View on PubMed)

Pagnesi M, Staal L, Ter Maaten JM, Beldhuis IE, Cotter G, Davison BA, Jongs N, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Lombardi CM, Adamo M, Severin T, Gimpelewicz C, Voors AA, Teerlink JR, Metra M. Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial. JACC Heart Fail. 2025 Mar;13(3):414-429. doi: 10.1016/j.jchf.2024.09.013. Epub 2024 Nov 27.

Reference Type DERIVED
PMID: 39614837 (View on PubMed)

Grand J, Miger K, Sajadieh A, Kober L, Torp-Pedersen C, Ertl G, Lopez-Sendon J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. Circ Heart Fail. 2022 Apr;15(4):e009199. doi: 10.1161/CIRCHEARTFAILURE.121.009199. Epub 2022 Feb 21.

Reference Type DERIVED
PMID: 35184572 (View on PubMed)

Matsue Y, Sama IE, Postmus D, Metra M, Greenberg BH, Cotter G, Davison BA, Felker GM, Filippatos G, Pang P, Ponikowski P, Severin T, Gimpelewicz C, Voors AA, Teerlink JR. Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. JACC Heart Fail. 2021 Dec;9(12):890-903. doi: 10.1016/j.jchf.2021.07.001. Epub 2021 Oct 6.

Reference Type DERIVED
PMID: 34627724 (View on PubMed)

Grand J, Miger K, Sajadieh A, Kober L, Torp-Pedersen C, Ertl G, Lopez-Sendon J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. J Am Heart Assoc. 2021 Sep 21;10(18):e022288. doi: 10.1161/JAHA.121.022288. Epub 2021 Sep 13.

Reference Type DERIVED
PMID: 34514815 (View on PubMed)

Loungani RS, Teerlink JR, Metra M, Allen LA, Butler J, Carson PE, Chen CW, Cotter G, Davison BA, Eapen ZJ, Filippatos GS, Gimpelewicz C, Greenberg B, Holbro T, Januzzi JL Jr, Lanfear DE, Pang PS, Pina IL, Ponikowski P, Miller AB, Voors AA, Felker GM. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. JACC Heart Fail. 2020 Dec;8(12):999-1008. doi: 10.1016/j.jchf.2020.09.010. Epub 2020 Nov 11.

Reference Type DERIVED
PMID: 33189635 (View on PubMed)

Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendano P, Bacal F, Bohm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverria LE, Ferrari R, Goland S, Goncalvesova E, Goudev A, Kober L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Spinar J, Squire I, Stepinska J, Van Mieghem W, von Lewinski D, Wikstrom G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsody P, Gimpelewicz C; RELAX-AHF-2 Committees Investigators. Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med. 2019 Aug 22;381(8):716-726. doi: 10.1056/NEJMoa1801291.

Reference Type DERIVED
PMID: 31433919 (View on PubMed)

Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Gimpelewicz C, Boer-Martins L, Wernsing M, Hua TA, Severin T, Metra M. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail. 2017 Jun;19(6):800-809. doi: 10.1002/ejhf.830. Epub 2017 Apr 28.

Reference Type DERIVED
PMID: 28452195 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-001498-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CRLX030A2301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ertugliflozin in Chronic Heart Failure
NCT04438213 RECRUITING PHASE2
Intravenous Allopurinol in Heart Failure
NCT00181155 COMPLETED PHASE2